WHIP 164

Drug Profile

WHIP 164

Alternative Names: WHI-P164

Latest Information Update: 30 Apr 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antihyperlipidaemics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Atherosclerosis; Hypercholesterolaemia

Most Recent Events

  • 28 Feb 2000 A preclinical study has been added to the adverse events section, the pharmacokinetics section and the Hyperlipidaemia pharmacodynamics section
  • 14 Sep 1998 New profile
  • 14 Sep 1998 Preclinical development for Hypercholesterolaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top